Development asset linked to Seqirus USA in public FDA and regional records.
pharma · Influenza, Human · Influenza
Seqirus USA
Seqirus (Australia) Pty Ltd
Seqirus USA drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Summit, USA HQ
8 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Summit, USA
- Employees
- 8
- Programs
- 9
- Drugs
- 19
- Patents
- 0
Seqirus USA pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Seqirus USA drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
avacopan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: C5a anaphylatoxin chemotactic receptor 1.
- Target
- C5a anaphylatoxin chemotactic receptor 1
- Mechanism
- C5a anaphylatoxin chemotactic receptor antagonist
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Seqirus USA's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
difelikefalin
Various (V03)Various (V03) compound in Seqirus USA's portfolio. Molecular target: Kappa-type opioid receptor.
- Target
- Kappa-type opioid receptor
- Mechanism
- Kappa opioid receptor agonist
-
Development asset linked to Seqirus USA in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
icosapent ethyl
Cardiovascular system (C10)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Seqirus USA in public FDA and regional records.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Seqirus USA's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Seqirus USA's portfolio.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Seqirus USA in public FDA and regional records.
-
pandemic influenza vaccine (h5n1) (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Seqirus USA's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
patiromer
Various (V03)Various (V03) compound in Seqirus USA's portfolio. Molecular target: Potassium.
- Target
- Potassium
- Mechanism
- Potassium chelating agent
-
sucroferric oxyhydroxide
Various (V03)Various (V03) compound in Seqirus USA's portfolio. Molecular target: Phosphate.
- Target
- Phosphate
- Mechanism
- Phosphate sequestering agent
-
US regulatory status: approved. Mechanism: Norepinephrine transporter inhibitor.
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Seqirus USA in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
trivalent influenza vaccine (recombinant, prepared in cell culture)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Seqirus USA's portfolio.
-
Development asset linked to Seqirus USA in public FDA and regional records.